Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Oct;61(4):412-413.
doi: 10.1165/rcmb.2019-0122ED.

CA Dreamin': Carbonic Anhydrase Inhibitors, Macrophages, and Pulmonary Hypertension

Larissa A Shimoda  1
Affiliations
Editorial

CA Dreamin': Carbonic Anhydrase Inhibitors, Macrophages, and Pulmonary Hypertension

Larissa A Shimoda. Am J Respir Cell Mol Biol. 2019 Oct.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Voelkel NF, Tamosiuniene R, Nicolls MR. Challenges and opportunities in treating inflammation associated with pulmonary hypertension. Expert Rev Cardiovasc Ther. 2016;14:939–951. - PMC - PubMed
    1. Pullamsetti SS, Savai R. Macrophage regulation during vascular remodeling: implications for pulmonary hypertension therapy. Am J Respir Cell Mol Biol. 2017;56:556–558. - PubMed
    1. El Kasmi KC, Stenmark KR. Contribution of metabolic reprogramming to macrophage plasticity and function. Semin Immunol. 2015;27:267–275. - PMC - PubMed
    1. D’Alessandro A, El Kasmi KC, Plecitá-Hlavatá L, Ježek P, Li M, Zhang H, et al. Hallmarks of pulmonary hypertension: mesenchymal and inflammatory cell metabolic reprogramming. Antioxid Redox Signal. 2018;28:230–250. - PMC - PubMed
    1. Hudalla H, Michael Z, Christodoulou N, Willis GR, Fernandez-Gonzalez A, Filatava EJ, et al. Carbonic anhydrase inhibition ameliorates inflammation and experimental pulmonary hypertension. Am J Respir Cell Mol Biol. 2019;61:512–524. - PMC - PubMed

Substances